Nuvalent (NASDAQ:NUVL) Stock Rating Lowered by Robert W. Baird

Nuvalent (NASDAQ:NUVL) was downgraded by equities researchers at Robert W. Baird from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Tuesday,Zacks.com reports.

Other equities analysts have also issued reports about the stock. Lifesci Capital lowered shares of Nuvalent from an “outperform” rating to a “hold” rating and set a $124.00 price objective on the stock. in a report on Tuesday. Raymond James Financial lowered shares of Nuvalent from an “outperform” rating to a “market perform” rating in a report on Tuesday. Wells Fargo & Company restated an “equal weight” rating and issued a $124.00 price objective (up from $116.00) on shares of Nuvalent in a report on Tuesday. Guggenheim lowered shares of Nuvalent from a “buy” rating to a “neutral” rating and cut their price objective for the company from $151.00 to $124.00 in a report on Wednesday. Finally, Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Nuvalent in a research note on Wednesday. Five investment analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $131.15.

Nuvalent Price Performance

Shares of NASDAQ NUVL opened at $123.35 on Tuesday. The company’s 50 day simple moving average is $103.44 and its 200 day simple moving average is $103.19. Nuvalent has a fifty-two week low of $71.13 and a fifty-two week high of $123.62. The firm has a market capitalization of $9.74 billion, a P/E ratio of -20.35 and a beta of 1.15.

Nuvalent (NASDAQ:NUVL) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($1.35) by ($0.04). During the same quarter last year, the business posted ($1.18) EPS. Sell-side analysts expect that Nuvalent will post -5.74 EPS for the current fiscal year.

Insider Activity

In other news, CFO Alexandra Balcom sold 11,430 shares of the stock in a transaction on Monday, June 1st. The shares were sold at an average price of $98.69, for a total transaction of $1,128,026.70. Following the completion of the sale, the chief financial officer owned 85,533 shares of the company’s stock, valued at $8,441,251.77. This represents a 11.79% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO James Richard Porter sold 30,000 shares of the stock in a transaction on Monday, June 8th. The stock was sold at an average price of $88.53, for a total transaction of $2,655,900.00. Following the sale, the chief executive officer directly owned 324,879 shares of the company’s stock, valued at $28,761,537.87. This represents a 8.45% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 126,953 shares of company stock worth $12,612,264 over the last three months. Company insiders own 5.02% of the company’s stock.

Institutional Investors Weigh In On Nuvalent

Several large investors have recently made changes to their positions in the stock. GAMMA Investing LLC increased its position in shares of Nuvalent by 47.6% during the fourth quarter. GAMMA Investing LLC now owns 335 shares of the company’s stock worth $34,000 after acquiring an additional 108 shares in the last quarter. Kennedy Capital Management LLC increased its position in shares of Nuvalent by 1.5% during the fourth quarter. Kennedy Capital Management LLC now owns 10,932 shares of the company’s stock worth $1,100,000 after acquiring an additional 163 shares in the last quarter. US Bancorp DE increased its position in shares of Nuvalent by 10.0% during the third quarter. US Bancorp DE now owns 2,070 shares of the company’s stock worth $179,000 after acquiring an additional 188 shares in the last quarter. EverSource Wealth Advisors LLC increased its position in shares of Nuvalent by 141.3% during the first quarter. EverSource Wealth Advisors LLC now owns 333 shares of the company’s stock worth $34,000 after acquiring an additional 195 shares in the last quarter. Finally, Principal Financial Group Inc. increased its position in shares of Nuvalent by 7.7% during the third quarter. Principal Financial Group Inc. now owns 3,290 shares of the company’s stock worth $285,000 after acquiring an additional 234 shares in the last quarter. Institutional investors own 97.26% of the company’s stock.

Trending Headlines about Nuvalent

Here are the key news stories impacting Nuvalent this week:

• Positive Sentiment: GSK’s $10.6 billion all-cash acquisition offer gives Nuvalent shareholders a clear exit value at $124.00 per share, which is the biggest reason the stock has increased. Reuters article on GSK deal
• Positive Sentiment: Market commentary says the deal makes strategic sense for GSK because Nuvalent adds a late-stage oncology pipeline, supporting confidence that the transaction is credible and financially meaningful. MarketBeat analysis of the acquisition
• Neutral Sentiment: Several shareholder law firms have launched investigations into whether the sale process and price are fair, which could create headline noise but does not change the announced terms. Business Wire article on investigation
• Neutral Sentiment: Analyst downgrades followed the takeover news, but their revised price targets remain close to the deal value, so these moves are unlikely to outweigh the acquisition catalyst. Analyst downgrade coverage
• Negative Sentiment: CEO James Richard Porter sold 30,000 shares, a modest negative sentiment signal that may reinforce the view that insiders have been reducing exposure ahead of the transaction. SEC insider filing

Nuvalent Company Profile

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.